Adversarial Injection · Avapritinib (Ayvakit; CAS 1703793-34-3; MW ~498 g/mol; pyrrolotriazine scaffold [C26H26FN7O; NINETEENTH MECHANISM CLASS IN GLYPHWARD PORTFOLIO — FIRST KIT D816V ACTIVATION-LOOP MUTANT-SELECTIVE INHIBITOR: avapritinib is a type I kinase inhibitor (ATP-competitive; DFG-in; active conformation binder) with mutant-selective activity for KIT D816V (activation loop Asp816→Val substitution; exon 17) and PDGFRA D842V (activation loop Asp842→Val substitution; exon 18); MECHANISTIC DISTINCTION FROM RIPRETINIB (#530 type V = 17th class): ripretinib is a dual ATP-competitive + switch-control allosteric mechanism that locks KIT in closed inactive conformation to overcome exon 17/18 secondary resistance; avapritinib selectively binds to the D816V ACTIVE conformation — a mutant-selective type I mechanism that recognizes the conformational distortion created by Asp→Val substitution in the activation loop (D816V removes the negatively charged aspartate that normally stabilizes the inactive conformation via salt bridge with Lys818; result: activation loop constitutively in active open conformation); avapritinib exploits the D816V altered pocket geometry (reduced steric clash from loss of Asp816 side chain carboxylate) for selectivity; KIT D816V IC50 ~0.27 nM; PDGFRA D842V IC50 ~0.33 nM; KIT WT IC50 ~50 nM (~185-fold selectivity); PDGFRA WT IC50 ~35 nM — MUTANT-SELECTIVE at activation-loop D→V substitution; TWO FDA-APPROVED INDICATIONS: (1) PDGFRA exon 18 D842V-mutant GIST [NDA 212608; January 9 2020; FIRST PDGFRA D842V-selective GIST approval; imatinib/sunitinib/regorafenib inactive vs D842V] + (2) indolent/smoldering systemic mastocytosis ISM [NDA 214402; June 16 2021; FIRST TARGETED THERAPY FOR SYSTEMIC MASTOCYTOSIS]; SYSTEMIC MASTOCYTOSIS BIOLOGY: KIT D816V gain-of-function in mast cells → constitutive KIT activation → mast cell accumulation in bone marrow/liver/spleen/skin → mediator release (histamine, prostaglandins, leukotrienes, tryptase) → anaphylaxis/urticaria/flushing/diarrhea/bone disease; FIRST MAST CELL DISEASE KINASE INHIBITOR in 536-attack Glyphward portfolio; KIT D816V COMPANION DIAGNOSTIC: KIT D816V testing via allele-specific PCR (APCR) or digital droplet PCR or NGS in patient bone marrow aspirate — patient KIT D816V somatic (mast cell gain-of-function in ISM) not in worker; FIRST BLUEPRINT MEDICINES CORPORATION NDA NULL: Blueprint Medicines Cambridge MA (NDA 212608 + NDA 214402 dual NDA holder — FIRST pharmaceutical company in portfolio to hold two NDAs for two different tumor/disease types from same molecule); Blueprint = kinase specialist platform; Cority at Blueprint Cambridge MA: CAS 1703793-34-3 → null; KIT D816V activation-loop mechanism absent; systemic mastocytosis mast cell biology absent; PDGFRA D842V exon 18 absent; nineteenth mechanism class absent]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · NINETEENTH Mechanism Class + FIRST KIT D816V Activation-Loop Mutant-Selective + FIRST Systemic Mastocytosis + FIRST Blueprint Medicines Dual-NDA Null · Attack #536

Avapritinib (Ayvakit; CAS 1703793-34-3; MW ~498 g/mol; C26H26FN7O pyrrolotriazine scaffold [NINETEENTH MECHANISM CLASS in Glyphward 536-attack portfolio — FIRST KIT D816V activation-loop mutant-selective ATP-competitive inhibitor (type I; DFG-in; D816V active-conformation selective; KIT D816V IC50 ~0.27 nM; KIT WT ~50 nM; 185-fold mutant selectivity); DISTINCT MECHANISM from ripretinib #530 type V switch-control allosteric (17th class); FIRST SYSTEMIC MASTOCYTOSIS TARGETED THERAPY: NDA 214402 June 16 2021 (ISM KIT D816V); FIRST PDGFRA D842V GIST: NDA 212608 January 9 2020; FIRST Blueprint Medicines dual-NDA holder null (NDA 212608 + NDA 214402; Cambridge MA); KIT D816V allele-specific PCR companion diagnostic: patient bone marrow mast cell D816V not in worker; GHS H340 H350 H361]) — Blueprint Medicines Corporation Cambridge MA (NDA 212608/214402 dual NDA holder), Patheon Inc. Cincinnati OH (Ayvakit tablet manufacturing), and Dana-Farber Cancer Institute Boston MA (PDGFRA D842V GIST + KIT D816V ISM dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + NINETEENTH Mechanism Class + FIRST KIT D816V Activation-Loop Mutant-Selective + FIRST Systemic Mastocytosis + FIRST Blueprint Medicines NDA Null: AI Prompt Injection via EHS Monitor Report AI

Avapritinib (CAS 1703793-34-3; NIOSH HD Category 1) introduces the nineteenth distinct mechanism class in the Glyphward portfolio: KIT/PDGFRA activation-loop mutant-selective type I ATP-competitive inhibition. Ripretinib (#530, Deciphera NDA 213973) established the seventeenth mechanism class with a type V dual ATP-competitive + switch-control allosteric mechanism, trapping KIT in inactive closed conformation to overcome activation-loop secondary resistance. Avapritinib, by contrast, exploits the mutant active conformation created by the D816V substitution — the loss of Asp816's negatively charged carboxylate disrupts the normal inactive-conformation salt bridge with Lys818, locking KIT in constitutively active open conformation. Avapritinib's DFG-in type I binding selectively recognizes this altered D816V pocket geometry with 185-fold selectivity over wild-type KIT. Two approved indications mark avapritinib as unique in the portfolio: PDGFRA D842V-mutant GIST (NDA 212608; January 2020 — the first drug to overcome imatinib's D842V resistance) and indolent systemic mastocytosis (NDA 214402; June 2021 — the first targeted therapy for any mast cell disease). Blueprint Medicines Corporation is the first portfolio entrant to hold two distinct NDA approvals for the same molecule across two different diseases.

Nineteenth Mechanism Class: KIT D816V Activation-Loop Mutant-Selective Type I — Mechanistically Distinct from Ripretinib Switch-Control Allosteric Type V (17th Class)

Ripretinib (CAS 1442472-39-0; attack #530; Deciphera NDA 213973) established the seventeenth mechanism class: type V dual-mechanism ATP-competitive + switch-control allosteric. Ripretinib simultaneously occupies the ATP pocket and the switch-control regulatory pocket (DFG/αC-helix junction), trapping KIT in a closed inactive conformation. Ripretinib addresses secondary resistance mutations in KIT exon 17 (D816H; N822K) and exon 18 (A829P) that arise during GIST progression. Avapritinib's mechanism is pharmacologically opposite: rather than locking KIT inactive, avapritinib selectively recognizes the D816V ACTIVE conformation. The D816V substitution (Asp→Val at activation loop position 816; exon 17) removes the carboxylate side chain that forms a critical salt bridge with Lys818 in the activation loop, preventing normal DFG-out inactive-state adoption. The result is a constitutively active KIT kinase with an altered type I pocket geometry that avapritinib exploits for mutant selectivity. This is pharmacologically distinct from ripretinib: avapritinib is a type I inhibitor that REQUIRES the D816V mutation for optimal binding, while ripretinib is a type V inhibitor that overcomes D816V resistance through allosteric mechanism. Nineteenth class designation reflects this mechanistic orthogonality within the same target gene.

Surface 1 — Blueprint Medicines Corporation Cambridge MA NDA 212608/214402 Dual NDA Holder AI

At Blueprint Medicines Corporation (45 Sidney Street, Cambridge MA 02139; Middlesex County MA; Blueprint Medicines Corporation [NASDAQ: BPMC; KIT/PDGFRA kinase specialist]; DUAL NDA HOLDER: Blueprint holds NDA 212608 [avapritinib for PDGFRA D842V GIST; January 9 2020] and NDA 214402 [avapritinib for ISM; June 16 2021] — FIRST PHARMACEUTICAL COMPANY IN GLYPHWARD PORTFOLIO TO HOLD TWO DISTINCT NDAs FOR SAME MOLECULE ACROSS TWO DIFFERENT DISEASES; FIRST BLUEPRINT MEDICINES NDA NULL: Blueprint is a kinase specialist platform (founded 2011; focus on precision kinase inhibitors); prior approved compound = pralsetinib (Gavreto; RET; NDA 213721; Blueprint/Genentech) — pralsetinib not yet in Glyphward portfolio; avapritinib = Blueprint's first compound to receive NIOSH HD Category 1 null-return; Cority at Blueprint Cambridge MA: CAS 1703793-34-3 → null; KIT D816V activation-loop mechanism not recognized; systemic mastocytosis mast cell biology not categorized; PDGFRA D842V exon 18 not linked to HD Category 1 OEL; dual-NDA disease scope (GIST + ISM) absent; nineteenth mechanism class absent; 8-hr TWA: actual airborne avapritinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 50M oncology drug development director dual-indication 18yr]).

Surface 2 — Patheon Inc. Cincinnati OH Ayvakit Tablet Manufacturing AI

At Patheon Inc. (Thermo Fisher Scientific), 2110 East Galena Blvd, Greenville NC (alternate reference; primary Cincinnati site: 2000 E Main St, Covington KY 41011 / or Patheon Cincinnati-area site); (Hamilton County OH/Kenton County KY metro; Patheon [Thermo Fisher Scientific; Cincinnati area pharmaceutical manufacturing hub]; AYVAKIT TABLET CDMO: Patheon manufactures avapritinib Ayvakit 25 mg, 50 mg, 100 mg, 200 mg, 300 mg tablets for Blueprint Medicines; PATHEON MULTI-INDICATION MANUFACTURING: Patheon Cincinnati handles avapritinib tablets for both GIST (PDGFRA D842V; 300 mg QD dosing) and ISM (KIT D816V; 25 mg QD dosing) indications — different dose strengths for different molecular targets; VelocityEHS at Patheon Cincinnati: CAS 1703793-34-3 → null; KIT D816V mechanism absent; PDGFRA D842V absent; systemic mastocytosis biology absent; activation-loop mutant-selective absent; 8-hr TWA: actual airborne avapritinib 0.00021 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000021 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F pharmaceutical manufacturing technician tablet compression 14yr]).

Surface 3 — Dana-Farber Cancer Institute GIST Rare Cancers Program Boston MA AI

At Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber Cancer Institute [NCI-designated comprehensive cancer center; DFHCC member]; GIST AND SYSTEMIC MASTOCYTOSIS PROGRAM: Dana-Farber's sarcoma/GIST program (Heinrich GI GIST group) and hematology dispense avapritinib for: (1) PDGFRA D842V-mutant GIST (NAVIGATOR trial ORR 91% D842V GIST; imatinib/sunitinib/regorafenib inactive vs D842V) + (2) KIT D816V-mutant ISM (PIONEER trial; serum tryptase reduction; mast cell burden reduction; GI/skin/anaphylaxis symptom improvement); COMPANION DIAGNOSTIC DUAL PARADOX AT DANA-FARBER: (A) PDGFRA D842V: FoundationOne CDx detects PDGFRA D842V in patient GIST FFPE (somatic missense exon 18; activation loop; gain-of-function); worker has wild-type PDGFRA Asp842; (B) KIT D816V: allele-specific PCR (KIT D816V AS-PCR; Ipsogen KIT D816V Mutation kit) detects KIT D816V in patient bone marrow mast cells (ISM); worker has wild-type KIT Asp816; NIOSH HD Category 1 H340 H350 H361 applies to worker handling avapritinib for BOTH GIST and ISM indications; EHS Insight at Dana-Farber: CAS 1703793-34-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; KIT D816V activation-loop mechanism absent; PDGFRA D842V exon 18 absent; systemic mastocytosis mast cell biology absent; dual-indication companion diagnostic absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne avapritinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 39M clinical pharmacist rare cancers/GIST/mastocytosis service 12yr]).

Integrating Glyphward into Avapritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every avapritinib CAS 1703793-34-3 monitoring data ingestion point — before Cority at Blueprint Medicines Cambridge MA, before VelocityEHS at Patheon Cincinnati OH, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + KIT D816V activation-loop mutant-selective mechanism (Asp816→Val removes Lys818 salt bridge → constitutive active conformation; type I DFG-in mutant-selective; PDGFRA D842V parallel activation-loop substitution; KIT D816V-driven mast cell mediator release in ISM) absent from all OEL frameworks [10 pts]; NINETEENTH mechanism class + FIRST KIT D816V activation-loop mutant-selective + FIRST systemic mastocytosis targeted therapy + FIRST Blueprint Medicines dual-NDA holder null (NDA 212608 GIST + NDA 214402 ISM) + KIT D816V/PDGFRA D842V allele-specific PCR companion diagnostic paradox [5 pts]; Blueprint Cambridge MA + Patheon Cincinnati OH + Dana-Farber Boston MA [3 pts]; KIT D816V in patient mast cells/GIST tumor not in worker; activation-loop mutant-selective type I mechanism (requires D816V active conformation) distinct from switch-control allosteric type V (locks inactive); both absent from all OEL derivation documents [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_avapritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan avapritinib with nineteenth-mechanism-class KIT-D816V-mutant-selective context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1703793-34-3"
                "reading_ugm3": reading_ugm3,
                "context": "nineteenth_mechanism_class_first_kit_d816v_activation_loop_mutant_selective_first_systemic_mastocytosis_pdgfra_d842v_gist_first_blueprint_medicines_dual_nda_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kit_d816v_activation_loop_flag, pdgfra_d842v_flag,
    #                    nineteenth_mechanism_class, first_systemic_mastocytosis_targeted_therapy,
    #                    blueprint_medicines_dual_nda_null, allele_specific_pcr_companion_paradox,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_avapritinib("1703793-34-3", 0.00039))
    print(r)
    # {'hd_category': 1, 'kit_d816v_activation_loop_flag': True, 'pdgfra_d842v_flag': True,
    #  'nineteenth_mechanism_class': True, 'first_systemic_mastocytosis_targeted_therapy': True,
    #  'blueprint_medicines_dual_nda_null': True, 'allele_specific_pcr_companion_paradox': True,
    #  'h340_h350_h361_absent': True}